NO20085131L - Lyofiliserte preparater av anti-EGFR-antistoffer - Google Patents

Lyofiliserte preparater av anti-EGFR-antistoffer

Info

Publication number
NO20085131L
NO20085131L NO20085131A NO20085131A NO20085131L NO 20085131 L NO20085131 L NO 20085131L NO 20085131 A NO20085131 A NO 20085131A NO 20085131 A NO20085131 A NO 20085131A NO 20085131 L NO20085131 L NO 20085131L
Authority
NO
Norway
Prior art keywords
egfr antibodies
lyophilized preparations
lyophilized
stable
present
Prior art date
Application number
NO20085131A
Other languages
English (en)
Inventor
Meera Agarkhed
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of NO20085131L publication Critical patent/NO20085131L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Én utførelsesform tilveiebringer den foreliggende oppfinnelse en stabil, lyofilisert fortnulering som omfatter et anti-EGFR-antistoff som fortrinnsvis er cetuximab, lactobionsyre og en buffer som fortrinnsvis er histidin. I én foretrukket utførelsesform tilveiebringer den foreliggende oppfinnelse en stabil, lyofilisert formulering som omfatter omtrent 50 mg/ml til omtrent 140 mg/ml av erbitux, omtrent 0,125% lactobionsyre, omtrent 25 mM histidinbuffer ved en pH på omtrent 6,0, omtrent 0,005% Tween 80 og omtrent 1,875% glysin.
NO20085131A 2006-06-14 2008-12-09 Lyofiliserte preparater av anti-EGFR-antistoffer NO20085131L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14
PCT/US2007/071119 WO2007147001A2 (en) 2006-06-14 2007-06-13 Lyophilized formulations of anti-egfr antibodies

Publications (1)

Publication Number Publication Date
NO20085131L true NO20085131L (no) 2009-03-13

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085131A NO20085131L (no) 2006-06-14 2008-12-09 Lyofiliserte preparater av anti-EGFR-antistoffer

Country Status (18)

Country Link
US (1) US20100158925A1 (no)
EP (1) EP2029163A4 (no)
JP (1) JP2009540015A (no)
KR (1) KR20090021298A (no)
CN (1) CN101466404A (no)
AU (1) AU2007260769A1 (no)
BR (1) BRPI0713421A2 (no)
CA (1) CA2654794A1 (no)
CR (1) CR10493A (no)
EA (1) EA200870538A1 (no)
EC (1) ECSP088962A (no)
IL (1) IL195794A0 (no)
MA (1) MA30515B1 (no)
MX (1) MX2008015852A (no)
NO (1) NO20085131L (no)
TN (1) TNSN08511A1 (no)
WO (1) WO2007147001A2 (no)
ZA (1) ZA200810456B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
AU2010320515B2 (en) * 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
CN103108658B (zh) * 2010-07-02 2015-08-19 米迪缪尼有限公司 抗体制剂
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
MX2016003256A (es) * 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CN106470697B (zh) * 2014-09-16 2019-10-25 兴盟生物医药(苏州)有限公司 抗egfr抗体以及其用途
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN108602827B (zh) 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
US10940185B2 (en) 2016-12-28 2021-03-09 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
CA3287794A1 (en) 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
SG11202011538RA (en) * 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
CN114423499A (zh) * 2019-06-06 2022-04-29 佳努克斯治疗公司 与肿瘤激活的t细胞衔接子相关的组合物和方法
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
WO2022035866A1 (en) 2020-08-11 2022-02-17 Janux Therapeutics, Inc. Cleavable linker compositions and methods
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
EP2332990A1 (en) * 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
AU2007215012A1 (en) * 2006-02-15 2007-08-23 Imclone Llc Antibody formulation

Also Published As

Publication number Publication date
JP2009540015A (ja) 2009-11-19
CA2654794A1 (en) 2007-12-21
KR20090021298A (ko) 2009-03-02
AU2007260769A1 (en) 2007-12-21
TNSN08511A1 (en) 2010-04-14
WO2007147001A3 (en) 2008-07-10
MX2008015852A (es) 2009-02-23
EA200870538A1 (ru) 2009-04-28
EP2029163A4 (en) 2010-08-11
BRPI0713421A2 (pt) 2012-03-13
ZA200810456B (en) 2009-12-30
MA30515B1 (fr) 2009-06-01
EP2029163A2 (en) 2009-03-04
US20100158925A1 (en) 2010-06-24
ECSP088962A (es) 2009-01-30
IL195794A0 (en) 2011-08-01
CR10493A (es) 2009-02-26
WO2007147001A2 (en) 2007-12-21
CN101466404A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
NO20085131L (no) Lyofiliserte preparater av anti-EGFR-antistoffer
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
TNSN07020A1 (en) Her2 antibody composition
NZ719036A (en) Anti-pdl1 antibody formulations
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
MX2018014395A (es) Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
EA200702402A1 (ru) Агенты, связывающие склеростин
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
AR092216A1 (es) Formulaciones estables de anticuerpos contra tslp
BRPI0514340A (pt) formulações de estabilização
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
NO20080612L (no) Immunokonjugatpreparater
UY32279A (es) Composiciones estables de anticuerpos y métodos para estabilizarlas
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
EP1855719A4 (en) NEUTRALIZING MONOCLONAL ANTIBODIES TO CORONAVIRES IN CONNECTION WITH HEAVY ACUTE RESPIRATORY SYNDROME
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
BRPI0921261A2 (pt) anticorpos que se ligam imunoespecificamente a peptídeos igf-1 humanos modificados , hibridoma, polipeptídeo isolado, ácido nucleico que codifica um anticorpo, vetor compreendendo um ácido nucléico, célula hospedeira compreendendo um vetor, ensaio imunosorvente ligado a enzima aperfeiçoado (elisa), método de manter uma dose ótima de igf-1/e modificada, método cromatográfico de afinidade aperfeiçoado e uso de igf-1/e modificado.
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
PT1105503E (pt) Guanililciclase humana soluvel alfal/betal (hsgc alfal/betal) isolada e purificada
PE20090767A1 (es) Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application